menu
    • menu

    Company profile for Bausch Health

    NEW Drugs in Dev: 45
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bausch Health is focused on improving people’s lives with our health care products. We are delivering on our commitments to patients, health care providers, other stakeholders and society, as we build an innovative company dedicated to advancing global health. We manufacture and market a broad range of branded and generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses...
    Bausch Health is focused on improving people’s lives with our health care products. We are delivering on our commitments to patients, health care providers, other stakeholders and society, as we build an innovative company dedicated to advancing global health. We manufacture and market a broad range of branded and generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic devices) directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bausch HealthCanada Flag
    Country
    Country
    Canada
    Address
    Address
    2150 St. Elzear Blvd. WestLaval, Quebec H7L 4A8
    Telephone
    Telephone
    +1 (800) 361-1448, +1 (514) 744-6792
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bauschhealth.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bausch-health-companies/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/bauschhealth

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bausch Announces 2026 Gastrointestinal Health Scholars Program
    Bausch Announces 2026 Gastrointestinal Health Scholars Program

    11 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bausch-health-announces-2026-gastrointestinal-health-scholars-program-302682672.html

    PR NEWSWIRE
    11 Feb 2026
    Share Share
    Bausch's $2B pursuit of Xifaxan successor hits wall Ph 3 failure
    Bausch's $2B pursuit of Xifaxan successor hits wall Ph 3 failure

    23 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/bausch-healths-2b-pursuit-xifaxan-successor-hits-wall-phase-3-failure

    FIERCE PHARMA
    23 Jan 2026
    Share Share
    Bausch Health Announces Q4 and FY 2025 Results on Feb. 18, 2026
    Bausch Health Announces Q4 and FY 2025 Results on Feb. 18, 2026

    21 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bausch-health-to-announce-fourth-quarter-and-full-year-2025-results-on-february-18-2026-302665838.html

    PR NEWSWIRE
    21 Jan 2026
    Share Share
    Bausch Health Concludes Exchange Offers With Final Results
    Bausch Health Concludes Exchange Offers With Final Results

    23 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-23/bausch-health-announces-final-results-and-expiration-of-exchange-offers

    PHARMIWEB
    23 Dec 2025
    Share Share
    Bausch Health Reports Early Exchange Offer Results
    Bausch Health Reports Early Exchange Offer Results

    08 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-08/bausch-health-announces-early-exchange-offer-results-for-exchange-offers

    PHARMIWEB
    08 Dec 2025
    Share Share
    Solta Medical Acquires Shibo Group to Bolster Its China Presence
    Solta Medical Acquires Shibo Group to Bolster Its China Presence

    01 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-01/bausch-healths-aesthetics-business-solta-medical-acquires-longtime-distribution-partner-the-shib

    PHARMIWEB
    01 Dec 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

    Details:

    Arestin (Minocycline) is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Periodontitis.


    Lead Product(s): Minocycline Hydrochloride

    Therapeutic Area: Dental and Oral Health Brand Name: Arestin

    Study Phase: Phase IProduct Type: Antibiotic

    Recipient: Case Western Reserve University

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 22, 2025

    blank

    01

    ORAPHARMA

    U.S.A
    arrow
    International Sweetener Colloquium
    Not Confirmed

    ORAPHARMA

    U.S.A
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Minocycline Hydrochloride

    Therapeutic Area : Dental and Oral Health

    Highest Development Status : Phase I

    Recipient : Case Western Reserve University

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

    Details : Arestin (Minocycline) is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Periodontitis.

    Product Name : Arestin

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    December 22, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

    Details:

    Rifaximin is a antibiotic drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Diarrhea.


    Lead Product(s): Rifaximin,Oral Rehydration Therapy (ORT)

    Therapeutic Area: Gastroenterology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibiotic

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 16, 2025

    blank

    02

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifaximin,Oral Rehydration Therapy (ORT)

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

    Details : Rifaximin is a antibiotic drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Diarrhea.

    Product Name : Undisclosed

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    December 16, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch Health Completes Acquisition of DURECT Corporation

    Details:

    Through the acquisition, Basuch will leverage DURECT's lead asset, DUR-928 (Larsucosterol), is an epigenetic modulator. It is being evaluated for alcoholic hepatitis.


    Lead Product(s): Larsucosterol

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Recipient: Durect Corporation

    Deal Size: $413.0 million Upfront Cash: $63.0 million

    Deal Type: Acquisition September 11, 2025

    blank

    03

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Larsucosterol

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Phase II

    Recipient : Durect Corporation

    Deal Size : $413.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Bausch Health Completes Acquisition of DURECT Corporation

    Details : Through the acquisition, Basuch will leverage DURECT's lead asset, DUR-928 (Larsucosterol), is an epigenetic modulator. It is being evaluated for alcoholic hepatitis.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : $63.0 million

    September 11, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch Acquires DURECT, Enhancing Liver Disease Solutions

    Details:

    Through the acquisition of Larsucosterol, a small molecule targeting DNMTs, the deal aims to advance epigenetic therapies.


    Lead Product(s): Larsucosterol

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: DUR-928

    Study Phase: Phase IIProduct Type: Steroid

    Recipient: Durect Corporation

    Deal Size: $413.0 million Upfront Cash: $63.0 million

    Deal Type: Acquisition July 29, 2025

    blank

    04

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Larsucosterol

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Phase II

    Recipient : Durect Corporation

    Deal Size : $413.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Bausch Acquires DURECT, Enhancing Liver Disease Solutions

    Details : Through the acquisition of Larsucosterol, a small molecule targeting DNMTs, the deal aims to advance epigenetic therapies.

    Product Name : DUR-928

    Product Type : Steroid

    Upfront Cash : $63.0 million

    July 29, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    George Medicines, Bausch Health Sign Licensing Agreement for GMRx2 in Canada

    Details:

    Under the terms of the licensing agreement, Bausch Health will hold the exclusive rights to commercialize, GMRx2 in Canada, Mexico etc. It is being evaluated for the treatment of hypertension.


    Lead Product(s): Telmisartan,Amlodipine,Indapamide

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Recipient: George Medicines

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 13, 2025

    blank

    05

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Telmisartan,Amlodipine,Indapamide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Recipient : George Medicines

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    George Medicines, Bausch Health Sign Licensing Agreement for GMRx2 in Canada

    Details : Under the terms of the licensing agreement, Bausch Health will hold the exclusive rights to commercialize, GMRx2 in Canada, Mexico etc. It is being evaluated for the treatment of hypertension.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    January 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rifaximin SSD in Dementia Trial

    Details:

    Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.


    Lead Product(s): Rifaximin

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Antibiotic

    Sponsor: Jasmohan Bajaj

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 05, 2024

    blank

    06

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifaximin

    Therapeutic Area : Neurology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Jasmohan Bajaj

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rifaximin SSD in Dementia Trial

    Details : Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.

    Product Name : Undisclosed

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    December 05, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Brodalumab in the Treatment of Immune-Related Adverse Events

    Details:

    Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): Brodalumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Sponsor: Bausch Health

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 04, 2024

    blank

    07

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Brodalumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Bausch Health

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Brodalumab in the Treatment of Immune-Related Adverse Events

    Details : Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 04, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet

    Details:

    Naltrexone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.


    Lead Product(s): Naltrexone,Bupropion Hydrochloride

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Miscellaneous

    Recipient: Laval University

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 01, 2024

    blank

    08

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naltrexone,Bupropion Hydrochloride

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase IV

    Recipient : Laval University

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet

    Details : Naltrexone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 01, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Health Canada Approves CABTREO™ for Acne Vulgaris in Patients 12 and Older

    Details:

    CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine indicated for acne vulgaris in patients 12 years of age and older.


    Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area: Dermatology Brand Name: Cabtreo

    Study Phase: Approved FDFProduct Type: Antibiotic

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 11, 2024

    blank

    09

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Health Canada Approves CABTREO™ for Acne Vulgaris in Patients 12 and Older

    Details : CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine indicated for acne vulgaris in patients 12 years of age and older.

    Product Name : Cabtreo

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    September 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rifaximin for the Secondary Prevention of Recurrent Pouchitis

    Details:

    Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pouchitis.


    Lead Product(s): Rifaximin

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibiotic

    Recipient: University of North Carolina

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 15, 2024

    blank

    10

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Bausch Health

    Canada
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifaximin

    Therapeutic Area : Trauma (Emergency, Injury, Surgery)

    Highest Development Status : Phase IV

    Recipient : University of North Carolina

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rifaximin for the Secondary Prevention of Recurrent Pouchitis

    Details : Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pouchitis.

    Product Name : Undisclosed

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    March 15, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Valeant Pharmaceuticals International, Inc and get a quotation

    Valeant Pharmaceuticals International, Inc is a supplier offers 3 products (APIs, Excipients or Intermediates).

    Find a price of Metformin bulk with DMF offered by Valeant Pharmaceuticals International, Inc

    Find a price of Pyridostigmine bulk with DMF offered by Valeant Pharmaceuticals International, Inc

    Find a price of Nitrazepam bulk offered by Valeant Pharmaceuticals International, Inc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search